Doit-on doser le marqueur circulant ECD/HER-2 chez les patientes atteintes d’un cancer mammaire ?

Mathelin, Carole; Croce, Sabrina; Rault, S.; Gharbi, Mouslim; Eichler, F.; Gairard, B.; Coumaros, G.; Koehl, C.

doi:10.1016/j.lpm.2010.10.004

Cited by 4 publications

(2 citation statements)

References 80 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, the ≥15 ng/mL standard should not be applied to NSCLC patients without validation studies. In contrast to these reports, more recent publications61,62 have concluded that larger sHER2 clinical studies are warranted and recommended because of the many previous positive publications about the clinical utility of sHER2 testing.…”

Section: Controversy Surrounding Serum Her2 Testing In All Breast Canmentioning

confidence: 96%

Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?

2013

View full text Add to dashboard Cite

The HER2 oncoprotein has emerged as an essential biomarker in the treatment of breast cancer patients. Once the primary breast cancer is removed, there is an increasing need to detect breast cancer recurrence as early as possible with the hope that earlier intervention with new anti-HER2 therapies will improve quality of life and increase overall survival. Numerous publications have shown that increasing blood levels of circulating HER2 is an early indicator of progression, particularly in HER2-positive patients and that the rise and fall parallels the clinical course of disease and independent of therapy. Many studies show that the HER2 status of the primary tumor may not fully and accurately reflect the HER2 status of recurrent cancer. Thus, elevated serum HER2 levels may be an early signal of the emergence of a HER2-positive metastatic tumor and therefore alert the physician to re-assess HER2 status using a tissue test.

show abstract

Section: Controversy Surrounding Serum Her2 Testing In All Breast Canmentioning

confidence: 96%

Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?

2013

View full text Add to dashboard Cite

show abstract

“…In the past, it has been used as an antidote for cyanide poisoning [22]. It is used in microbiological science for bacterial staining, in internal medicine as an antidote to drug-induced methemoglobinemia, ifosfamide-induced encephalopathy, and in surgical sciences for staining of the surgical field [22][23][24][25][26][27]. It was reported to show activity against Plasmodium falciparum strains and to have the potential to be used as an antimalarial agent in combination with other drugs [28].…”

Section: Introductionmentioning

confidence: 99%

In vitro activity of methylene blue and EMB agar on colistin-resistant A.baumannii: An experimental study

Gazel

Otkun

Akçalı

2019

Preprint

View full text Add to dashboard Cite

Background Colistin is one of the last resort antibiotics used against carbapenem-resistant Acinetobacter baumannii (AB); however, colistin resistance has been reported recently. Methylene blue (MB) is used in microbiology for staining, and in medicine as an antidote drug. Here, we investigated antimicrobial effects of MB and Eosin Methylene blue (EMB) agar against colistin-resistant AB strains. Methods The AB ATCC 19606 strain and 31 AB clinical isolates were included in the study. In the first round, ATCC strain and a clinical isolate were transformed into colistin-resistant forms, using Li's method, with increasing colistin concentrations. At each step, new MICs were determined and subcultures were inoculated to EMB and sheep blood agar (SBA). The colistin MIC values of the subcultures were also determined using Mueller Hinton Agar (MHA) containing 14 µg/mL MB. In the second round, colistin resistant clones of all collected clinical isolates (n=31) were obtained and screened to investigate their susceptibility to EMB agar by inoculating on SBA and EMB agar. Results At the beginning, the MICs of two strains were 0.5 µg/mL. At the last stage, both MICs had risen to 64 µg/mL. Subpopulations with high colistin resistance (>=32 µg/mL) were inhibited by MB and EMB agar, but could grow well on SBA. In MHA plates containing MB, the MICs decreased to the 0.5 µg/mL level for colistin-susceptible or moderately resistant clones. Additionally, clones with high colistin resistance showed atypical colony morphology on SBA. In the second round, MICs of the colistin resistant clones of all clinical isolates rose to 8 µg/mL after colistin exposure and 35% of those clinical isolates were inhibited by EMB agar while they could grow on SBA. Conclusion Highly resistant strains were totally inhibited by the effect of MB and EMB agar, while the MICs of the susceptible and moderate resistant clones decreased. EMB agar and MB may have inhibitory effects against colistin-resistant AB strains and MB may have a potential to be used as an antimicrobial drug. Secondly, using only EMB agar for subculturing may cause missing of colistin-resistant strains and giving incorrect identification or antibiogram reports in clinical microbiology laboratories.

show abstract

Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients

Sørensen

Jakobsen

Madsen

et al. 2013

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

Doit-on doser le marqueur circulant ECD/HER-2 chez les patientes atteintes d’un cancer mammaire ?

Cited by 4 publications

References 80 publications

Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?

Circulating HER2 Extracellular Domain: A Specific and Quantitative Biomarker of Prognostic Value in all Breast Cancer Patients?

In vitro activity of methylene blue and EMB agar on colistin-resistant A.baumannii: An experimental study

Serum HER-2: sensitivity, specificity, and predictive values for detecting metastatic recurrence in breast cancer patients

Contact Info

Product

Resources

About